The development site of ‘SKYCovione’, Korean Covid-19 vaccine developed by SK Bioscience (SK Bio) was open to the media.

SK Bio invited the media to the Andong L House on August 10th, and opened the production plant of SKYCovione to journalists.

SKYCovione is the ‘Korea’s first’ Covid-19 vaccine using synthetic antigens, under development led by SK Bio, which has financial support from the Bill & Melinda Gates Foundation (BMGF) and the Coalition for Epidemic Preparedness Innovations (CEPI), and applies the antigen technology of the Institute for Protein Design at University of Washington School of Medicine and the adjuvant AS03 of GlaxoSmithKline.